ACTG 303 - Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-up Study to ACTG 175. The hypothesis of this trial was that HIV-infected patients who had received prolonged combination therapy with zidovudine (ZDV) plus didanosine (ddl) or ADV plus zalcitabine (ddC) would show virologic and immunologic improvement upon addition of lamivudine (3TC) or after changing to ADV plus 3TC. The virologic and immunologic responses of these patients was expected to be influenced by virus load, CD4+ cell count, biologic phenotype of the HIV-1 isolate (ability of HIV-1 to induce syncytium formation in vitro), and presence or absence of symptoms of HIV disease at the time the new treatment regimens are instituted. The primary goals outlined in this trial were to carefully characterize subjects who have a well defined nucleoside exposure history with respect to the symptomatic state, their CD4 count trajectory, and their virologic profile, and to relate this to the response to new antiretroviral interventions in HIV infected patients who had been treated either with monotherapy (ZDV or ddl) or dual combination therapy (ZDV/ddl or ZDV/ddC) while participating in ACTG 175. Results of this trial are not yet available.
Showing the most recent 10 out of 1065 publications
